Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source.
What this means → 2026
Abstract
The authors’ words, as Science (New York, N.Y.) supplied them
Coronary collateral arteries have been proposed to form de novo through artery reassembly, a process in which arterial endothelial cells (ECs) migrate away from preexisting arteries and reassemble into new arteries. Using genetic tools that trace arterial ECs, we found that their contribution to collaterals is modest. Dual genetic lineage tracing revealed that capillary ECs, rather than arterial ECs, serve as the major building blocks for de novo collaterals. The capillary-to-collateral conversion is functionally crucial for cardiac repair. In addition, transient <i>Vegfa</i> expression through modified messenger RNA markedly promoted collateral formation. Mechanistically, vascular endothelial growth factor (VEGF) drives arterialization by regulating HES1 transcription through YY1/SETD1A-mediated H3K4 trimethylation. Collectively, these findings redefine the cellular origin and mechanism of coronary collateral formation and highlight its role in facilitating efficient cardiac repair.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Survodutide (BI 456906) corpus
ASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2023 · n=752 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.HumanASurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.Contemporary clinical trials · 2026 · 18.7% body-weight reduction at 46 weeks.reviewCNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.AnimalASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2HumanASurvodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026 · 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.HumanASurvodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026 · -12.2% mean change in body weight from baseline in the 3.6-mg group at week 76, 95% CI -13.6 to -10.8.Human